20 November 2026
The ABP tracks an athlete’s biological markers over time and identifies unusual changes in the rider’s blood profile which may be caused by the use of prohibited substance or method.¹ In Delio Fernandez Cruz’s case, independent experts unanimously concluded that the changes in his ABP values were highly likely to have been caused by a prohibited substance or method. The findings concerned samples collected during the Vuelta a Portugal on 28 July and 5 August 2015, and on 15 and 17 August 2023.
The UCI initially handled the results management process. The ITA subsequently took over the matter and conducted the disciplinary proceedings before the Tribunal on behalf of the UCI following the delegation of legal proceedings to the ITA in February 2026.²
On 12 November 2026, the Tribunal found that the rider had committed an ADRV for the use of a prohibited substance or a prohibited method under Article 2.2 of the UCI anti-doping rules.
The Tribunal imposed a four-year period of ineligibility on Delio Fernandez Cruz, from 12 November 2026 until 11 November 2030. It also disqualified all his individual results for two periods: from 28 July 2015, the date of the first abnormal sample, until 27 July 2019; and from 9 August 2023, the start of the 2023 Vuelta a Portugal, until the start of his period of ineligibility. A fine equal to 70 % of the average gross annual income earned from cycling was also imposed.
The rider and the relevant stakeholders, namely the UCI/ITA, the World Anti-Doping Agency and the rider’s National Anti-Doping Organisation (NADO), may appeal the Tribunal’s decision to the Appeals Division of the Court of Arbitration for Sport (CAS).
The ITA will not comment further on this case.
¹ The ABP is an individual electronic record that monitors specific biological variables over time and allows for the indirect detection of doping. The ITA manages the ABP program for cycling on behalf of the UCI, in collaboration with the Athlete Passport Management Unit (APMU) based in Lausanne, Switzerland. The APMU operates in association with the WADA-accredited laboratory in Lausanne and supports the evaluation of data through a panel of independent experts. When this expert panel unanimously concludes that the data reflects doping, the case is referred for results management.